The endocannabinoid system is a ubiquitous lipid signaling system involved in various regulatory functions throughout the body. The primary endocannabinoids, arachidonoylethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG), are released upon demand from lipid precursors and bind to cannabinoid (CB1) receptors in the brain or CB2 receptors in the peripheral tissues. Fatty acid amide hydrolase (FAAH) is a cytosolic serine hydrolase responsible for the degradation of fatty acid amides, including AEA. Finding inhibitors to FAAH could offer a beneficial approach toward the treatment of pain, obesity, and various neurological diseases where higher endocannabinoid activity would be beneficial. TheFAAH Inhibitor Screening Assay Kit provides a convenient fluorescence-based method for screening FAAH inhibitors. FAAH hydrolyzes AMC-arachidonoyl amide resulting in the release of the fluorescent product, 7-amino-4-methylcoumarin (AMC). The fluorophore can be easily analyzed using an excitation wavelength of 340-360 nm and an emission wavelength of 450-465 nm.
FAAH Assay Buffer (10X): 1 vial/5 ml; -20°C FAAH (human recombinant):2 vials/120μl; -80°CFAAH Substrate: 1 vial/1.5 ml; -20°C JZL 195 Inhibitor Assay Reagent: 1 vial; -20°C 96-Well Solid Plate (black): 1 plate; RT 96-Well Cover Sheet: 1 cover; RT